Secondary Progressive Multiple Sclerosis (SPMS) - Epidemiology Forecast to 2028

Publisher Name :
Date: 15-Jan-2019
No. of pages: 50
Delivery of the Report will take 2-3 working days once order is placed.

DelveInsight's "Secondary Progressive Multiple Sclerosis (SPMS) - Epidemiology Forecast, 2028" report provides a comprehensive analysis of the Secondary Progressive Multiple Sclerosis (SPMS) epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2028.

Markets Covered

- United States

- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

- Japan

Study Period: 2016-2028

Secondary Progressive Multiple Sclerosis (SPMS) Epidemiology

The epidemiology section covers the historical, current as well as forecasted epidemiology for Secondary Progressive Multiple Sclerosis (SPMS) in 7 major markets. The data is collected by understanding the disease, reviewing numerous studies conducted by countries and by exploring different surveys as well as reports. The Key opinion leaders' views are also taken into account to provide a deep understanding of the Secondary Progressive Multiple Sclerosis (SPMS) outlook. It also includes the explanation of changing trends of epidemiology outlining the Secondary Progressive Multiple Sclerosis (SPMS) scenario.

Secondary Progressive Multiple Sclerosis (SPMS) Epidemiology Segmentation

The epidemiology section is further segmented according to the patient pool characteristics, such as age-specific, type-specific, sub-type specific, gender-specific etc., thus providing an in-depth and high-quality analysis. The report also covers the prevalent/Incidence cases as well as the treatable cases as per the therapies available for the Secondary Progressive Multiple Sclerosis (SPMS) thereby presenting the trends with detailed analysis, with the assumptions undertaken. The data is presented in the form of graphs along with tables to effectively summarize the landscape.

Report Scope

- The report covers detailed overview of Secondary Progressive Multiple Sclerosis (SPMS) explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns

- It provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan

- The Secondary Progressive Multiple Sclerosis (SPMS) Report assesses the disease risk and burden and highlights the unmet needs

- It also helps to recognize the growth opportunities in the 7MM with respect to the patient population

Key strengths

- 10 Year Forecast

- 7MM Coverage

- Total Cases in Secondary Progressive Multiple Sclerosis (SPMS)

Key assessments

- Patient Segmentation in Secondary Progressive Multiple Sclerosis (SPMS)

- Secondary Progressive Multiple Sclerosis (SPMS) Risk & Burden

- Factors driving growth in a specific Secondary Progressive Multiple Sclerosis (SPMS) patient population

Secondary Progressive Multiple Sclerosis (SPMS) - Epidemiology Forecast to 2028

Table of Contents

1. Report Introduction
2. Secondary Progressive Multiple Sclerosis (SPMS) Epidemiology Overview at a Glance
2.1. Patient Share Distribution of Secondary Progressive Multiple Sclerosis (SPMS) in 2016
2.2. Patient Share Distribution of Secondary Progressive Multiple Sclerosis (SPMS) in 2028
3. Disease Background and Overview: Secondary Progressive Multiple Sclerosis (SPMS)
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
4.3. Total Prevalent/ Incident Patient Population of Secondary Progressive Multiple Sclerosis (SPMS) in 7MM - By Countries
5. Epidemiology of Secondary Progressive Multiple Sclerosis (SPMS) by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS)
5.1.3. Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) *
5.1.4. Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) *
5.1.5. Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS)
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS)
5.4.3. Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) *
5.4.4. Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) *
5.4.5. Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS)
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS)
5.5.3. Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) *
5.5.4. Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) *
5.5.5. Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS)
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS)
5.6.3. Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) *
5.6.4. Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) *
5.6.5. Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS)
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS)
5.7.3. Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) *
5.7.4. Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) *
5.7.5. Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS)
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS)
5.8.3. Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) *
5.8.4. Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) *
5.8.5. Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS)
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS)
5.9.3. Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) *
5.9.4. Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) *
5.9.5. Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS)
6. Unmet Needs of the Secondary Progressive Multiple Sclerosis (SPMS)
7. Appendix
8. Report Methodology
8.1. Sources
9. DelveInsight Capabilities
10. Disclaimer
11. About DelveInsight
*Indication Specific

List of Tables

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)*
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)*
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) *
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) *
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) *
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) *
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) *
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) *
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) *
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) *
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) *
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) *
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) *
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) *
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

List of Figures

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)*
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)*
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) *
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) *
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) *
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) *
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) *
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) *
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) *
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) *
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) *
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) *
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) *
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) *
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

  • Global Multiple Sclerosis Drugs Sales Market Report 2021
    Published: 19-Apr-2021        Price: US 4000 Onwards        Pages: 120
    The global Multiple Sclerosis Drugs market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Multiple Sclerosis Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2016-2027. Segment by Type - Injectable Medications - Or......
  • 2020-2025 Global Multiple Sclerosis Drugs Market Report - Production and Consumption Professional Analysis (Impact of COVID-19)
    Published: 01-Apr-2021        Price: US 3360 Onwards        Pages: 112
    Multiple sclerosis (MS) is the most common disabling neurological disease in young people worldwide. This report elaborates the market size, market characteristics, and market growth of the Multiple Sclerosis Drugs industry, and breaks down according to the type, application, and consumption area of Multiple Sclerosis Drugs. The report also conducted a PESTEL analysis of the industry to study the main influencing factors and entry barriers of the industry. In Chapter 3.4 of......
  • Global Multiple Sclerosis Drugs Market Analysis 2016-2020 and Forecast 2021-2026
    Published: 24-Mar-2021        Price: US 2980 Onwards        Pages: 79
    Snapshot The global Multiple Sclerosis Drugs market size is estimated at xxx million USD with a CAGR xx% from 2016-2020 and is expected to reach xxx Million USD in 2021 with a CAGR xx% from 2021 to 2026. The report begins from overview of Industry Chain structure, and describes industry environment, then analyses market size and forecast of Multiple Sclerosis Drugs by product, region and application, in addition, this report introduces market competition situation among the vendors ......
  • Global Multiple Sclerosis Market Research Report with Opportunities and Strategies to Boost Growth- COVID-19 Impact and Recovery
    Published: 16-Mar-2021        Price: US 3500 Onwards        Pages: 113
    Multiple sclerosis (MS) is a chronic inflammatory neuropathy characterized by demyelination, axonal transection, and neurodegeneration in the central nervous system. Based on the Multiple Sclerosis market development status, competitive landscape and development model in different regions of the world, this report is dedicated to providing niche markets, potential risks and comprehensive competitive strategy analysis in different fields. From the competitive advantages of different types ......
  • Global Multiple Sclerosis Drugs Market Research Report 2021
    Published: 14-Jan-2021        Price: US 2900 Onwards        Pages: 91
    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth. Segment by Type - Injectable Medications - Oral Medications - Others Segment by Application - Adults......
  • Global Fingolimod Market Research Report 2021, Forecast to 2026
    Published: 13-Jan-2021        Price: US 2680 Onwards        Pages: 132
    The report forecast global Fingolimod market to grow to reach xx Million USD in 2021 with a CAGR of xx% during the period of 2021-2026. Projected and forecast revenue values are in constant U.S. dollars, unadjusted for inflation. Product values and regional markets are estimated by market analyst, data analyst and people from related industry, based on companys' revenue and applications market respectively." The report demonstrates detail coverage of Fingolimod industry and......
  • Global Fingolimod Professional Survey Report 2021, Forecast to 2026
    Published: 13-Jan-2021        Price: US 3280 Onwards        Pages: 103
    The report forecast global Fingolimod market to grow to reach xx Million USD in 2021 with a CAGR of xx% during the period of 2021-2026. Projected and forecast revenue values are in constant U.S. dollars, unadjusted for inflation. Product values and regional markets are estimated by market analyst, data analyst and people from related industry, based on companys' revenue and applications market respectively." The report demonstrates detail coverage of Fingolimod industry and......
  • Global Fingolimod Market Research Report 2021
    Published: 04-Jan-2021        Price: US 2900 Onwards        Pages: 91
    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth. Segment by Type - Oral - Injection Segment by Application - Medical Field - Science Research Field......
  • Multiple Sclerosis Drugs Market Status and Trend Analysis 2017-2026 (COVID-19 Version)
    Published: 21-Dec-2020        Price: US 3000 Onwards        Pages: 88
    Summary Further key aspects of the report indicate that: Chapter 1: Research Scope: Product Definition, Type, End-Use & Methodology Chapter 2: Global Industry Summary Chapter 3: Market Dynamics Chapter 4: Global Market Segmentation by region, type and End-Use Chapter 5: North America Market Segmentation by region, type and End-Use Chapter 6: Europe Market Segmentation by region, type and End-Use Chapter 7: Asia-Pacific Market Segmen......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs